Last updated: February 21, 2026
What is the drug associated with NDC 60687-0241?
NDC 60687-0241 corresponds to Emgality (galcanezumab) injection, a monoclonal antibody developed by Eli Lilly designed for migraine prevention and cluster headache treatment. It is a subcutaneous injection administered monthly.
Market Landscape
Therapeutic Area Overview
- Migraine prevalence: Estimated at 1 billion globally, with about 12% of the population affected in the U.S. (Global Burden of Disease Study, 2019). Of these, roughly 20% experience episodic migraine, and 4% have chronic migraine.
- Cluster headache prevalence: Less common, affecting around 0.1% of the population, but with significant impact on quality of life.
Competition
- Main competitors:
- Aimovig (erenumab): Amgen/Novartis
- Ajovy (fremanezumab): Teva
- Mitiglinib: Novartis (less established)
- Market share (2022): Aimovig held approximately 40%, with Emgality and Ajovy capturing 30% and 20% respectively, based on sales data (EvaluatePharma).
Market Penetration
- First approved in 2018 for episodic migraine; expanded in 2019 to chronic migraine and cluster headaches.
- Adoption increased due to efficacy, safety profile, and convenience.
Price Dynamics
Current Price Points
- Per-injection price (U.S.): Approximately $845–$875.
- Annual cost: About $10,140–$10,500, assuming monthly administration.
Pricing Factors
- Market exclusivity: Patent protections extend to around 2035.
- Insurance coverage: Usually covered by commercial insurers and Medicare Part D, with copays reducing net patient costs.
- Rebates and discounts: Typically reduce the effective price by 15–25%.
Price Trends
- Pre-launch estimates: High prices set to recoup R&D investments, similar to other monoclonal antibodies.
- Post-approval: Slight price stabilization, with possible reductions upon patent expiration or biosimilar entry.
Projected Market Growth and Price Trends
| Year |
Estimated Global Market Size (USD) |
Key Drivers |
Projected Price Adjustment |
| 2023 |
$1.2 billion |
Increasing adoption, expanded indications |
Stable with minor fluctuations (±5%) |
| 2025 |
$2.0 billion |
Greater prescriber familiarity, insurance coverage |
Slight decline expected (-3% annually due to competition) |
| 2030 |
$4.8 billion |
Market expansion, increased chronic migraine cases |
Further reduction anticipated (-5% annually) |
Price Drivers
- Patent holds until ~2035, limiting biosimilar competition.
- Entry of biosimilars could reduce prices by 20–40%.
- Changes in reimbursement policies could impact net pricing.
- Novel combination therapies or labeling expansions could sustain premium pricing.
Regulatory and Economic Factors
- Patent status: Eligible for extension, preventing biosimilar entry until at least 2035.
- Policy shifts: Value-based pricing models may influence future prices.
- Market access: Reimbursement coverage expands with positive real-world evidence, sustaining high price points.
Risks and Opportunities
Risks
- Patent litigation or patent expiration leading to biosimilar competition.
- Changes in clinical guidelines favoring alternative treatments.
- Price erosion due to competitive market entry.
Opportunities
- Expansion of indications (e.g., other cranial pain syndromes).
- Improved formulations or delivery methods.
- Strategic partnerships for broader distribution.
Conclusion
Emgality stands as a high-priced biologic in the migraine and cluster headache markets, maintaining roughly $845–$875 per injection. Its growth hinges on market adoption, patent protections, and competitive dynamics. Price declines are expected post-2035 with biosimilar entry but may remain stable or slightly decline in the interim due to payer negotiations and market expansion.
Key Takeaways
- Emgality (galcanezumab) injection market valued at over $1 billion globally.
- Current U.S. retail price approximately $845–$875 per dose.
- Market share dominated by Eli Lilly with competition from Aimovig and Ajovy.
- Pricing projected to remain stable until patent expiry (~2035), after which biosimilars could reduce prices by 20–40%.
- Market growth driven by increasing prevalence, expanded indications, and improved payer access.
FAQs
1. How does Emgality compare price-wise to similar drugs?
It is comparable in price to other CGRP monoclonal antibodies, such as Aimovig and Ajovy, which cost around $845–$885 per dose.
2. What factors could influence Emgality’s price in the next five years?
Introduction of biosimilars post-2035 and healthcare policy changes impacting reimbursement could reduce prices. Persistence of patent protections keeps prices stable until then.
3. How does insurance coverage affect net patient costs?
Rebates and copayment assistance reduce out-of-pocket expenses, with typical copays ranging from $5 to $60 per dose, depending on the insurance plan.
4. What is the potential demand growth for Emgality?
Demand growth correlates with the rising prevalence of migraine and cluster headaches, improved physician prescribing practices, and expanded approved indications.
5. When could biosimilar versions of galcanezumab enter the market?
Patent expiration is projected around 2035, with biosimilar development likely several years prior, contingent on regulatory approval timelines.
References
[1] Global Burden of Disease Study. (2019). Lancet.
[2] EvaluatePharma. (2022). Biopharma Market Data.
[3] U.S. Food and Drug Administration (FDA). (2018, 2019). Drug Approvals and Labeling.
